KMPH

KemPharm, Inc. (KMPH) | Rumor.io

KemPharm

KMPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KMPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

May 7

KemPharm, Inc. (KMPH) is a pharmaceutical company focused on developing medications for pain management and other conditions.
There is no market-relevant information provided in the available social media post.
No other information is available as the post does not discuss the company's financial performance or any other relevant market data.

Generated by AI

Sentiment

Of the messages about KMPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -100
Bearish	—	—	—	100% new

Bullish· Jun 11

$KMPH has significant room for growth, with a potential price target of $30 by the end of the year.
The company's new ADD drug is revolutionary, working with only one pill a day, and sales are just starting with approval already given.
The stock is expected to continue its upward trend, with a multi-billion dollar company possible in the near future, and a price target of $20-$30.

Bearish· Mar 26

The commenter expresses regret over not investing in KemPharm, implying that the company's stock may be a good opportunity.
The commenter believes that investing in "dying business models" based on internet advice is a bad idea.
The commenter implies that KemPharm's medical technology and medications have the potential to generate significant returns.

Generated by AI

Topics

Of the messages about KMPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	50%	50%	50%	5.88%
Announcements	0%	0%	0%	88.24%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	50%	50%	50%	5.88%
Technical Analysis	0%	0%	0%	0%

Earnings· Aug 9

KemPharm, Inc. is hosting a Q2 earnings call today at 4:30pm Eastern.
The call will be streamed live, with a replay available afterwards.
Investors can access the call through the provided link.

Announcements· Nov 29

KemPharm, Inc. (KMPH) announced the appointment of Christopher Posner as a new independent director.
The appointment was made in an 8-K filing with the SEC on November 28.
Posner's appointment is seen as a significant development for the company, with various news sources highlighting the announcement.

Technical Analysis· Mar 3

$KMPH is up 71% with 9M volume and tight spreads, making it a stock to watch, particularly due to its strong catalyst of FDA approval for its ADHD drug.
The stock is currently moving on short sale restriction, with most hands selling and big hands waiting for it to fall before jumping back in.
A potential pop could happen if $KMPH reaches around $13.00, possibly after 12PM, but this is speculative and subject to market conditions.

Generated by AI

Community

Of the messages about KMPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	60%
Newcomers	100%	100%	100%	40%

Regulars· Nov 18

Kempharm has received FDA Orphan Drug Designation for serdexmethylphenidate (SDX), a treatment for idiopathic hypersomnia.
Analysts covering Kempharm have been impressed with the company's advancements, with some even calling the stock "very easy to own".
The company's treatment, serdexmethylphenidate, has the potential for over $100M in annual net sales, with only 7,692 scripts per week needed to achieve this revenue.

Newcomers· Jan 24

The newcomer is concerned about the significant drop in price of KemPharm, Inc. ($KMPH) by 5.9%.
The newcomer thinks KemPharm, Inc. ($KMPH) has a nice chart, but is too small in terms of volume and market capitalization for their investment style.
The newcomer shares a personal experience where they lost money on KemPharm, Inc. ($KMPH) after a medicine trial succeeded, attributing it to the power of hedge funds.

Generated by AI

Also Discussed

Investors talking about KMPH also mention

#	Name	Attention
1	ATNX - Athenex, Inc.	——
2	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
3	Iterum Therapeutics plcITRM	0%0
4	Onconova Therapeutics IncONTX	0%0
5	Aquestive Therapeutics Inc.AQST	0%+0
6	UWM Holdings CorporationUWMC	0%0
7	Werewolf Therapeutics Inc.HOWL	0%0
8	GHSI - Guardion Health Sciences, Inc.	——
9	GLDN - Nicholas Gold Income ETF	——
10	GRIL - Muscle Maker, Inc.	——

KemPharm, Inc.

Location

Social

What share of all stock conversation is about KMPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

May 7

KemPharm, Inc. (KMPH) is a pharmaceutical company focused on developing medications for pain management and other conditions.
There is no market-relevant information provided in the available social media post.
No other information is available as the post does not discuss the company's financial performance or any other relevant market data.

Generated by AI

Sentiment

Of the messages about KMPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -100
Bearish	—	—	—	100% new

Bullish· Jun 11

$KMPH has significant room for growth, with a potential price target of $30 by the end of the year.
The company's new ADD drug is revolutionary, working with only one pill a day, and sales are just starting with approval already given.
The stock is expected to continue its upward trend, with a multi-billion dollar company possible in the near future, and a price target of $20-$30.

Bearish· Mar 26

The commenter expresses regret over not investing in KemPharm, implying that the company's stock may be a good opportunity.
The commenter believes that investing in "dying business models" based on internet advice is a bad idea.
The commenter implies that KemPharm's medical technology and medications have the potential to generate significant returns.

Generated by AI

Topics

Of the messages about KMPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	50%	50%	50%	5.88%
Announcements	0%	0%	0%	88.24%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	50%	50%	50%	5.88%
Technical Analysis	0%	0%	0%	0%

Earnings· Aug 9

KemPharm, Inc. is hosting a Q2 earnings call today at 4:30pm Eastern.
The call will be streamed live, with a replay available afterwards.
Investors can access the call through the provided link.

Announcements· Nov 29

KemPharm, Inc. (KMPH) announced the appointment of Christopher Posner as a new independent director.
The appointment was made in an 8-K filing with the SEC on November 28.
Posner's appointment is seen as a significant development for the company, with various news sources highlighting the announcement.

Technical Analysis· Mar 3

$KMPH is up 71% with 9M volume and tight spreads, making it a stock to watch, particularly due to its strong catalyst of FDA approval for its ADHD drug.
The stock is currently moving on short sale restriction, with most hands selling and big hands waiting for it to fall before jumping back in.
A potential pop could happen if $KMPH reaches around $13.00, possibly after 12PM, but this is speculative and subject to market conditions.

Generated by AI

Community

Of the messages about KMPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	60%
Newcomers	100%	100%	100%	40%

Regulars· Nov 18

Kempharm has received FDA Orphan Drug Designation for serdexmethylphenidate (SDX), a treatment for idiopathic hypersomnia.
Analysts covering Kempharm have been impressed with the company's advancements, with some even calling the stock "very easy to own".
The company's treatment, serdexmethylphenidate, has the potential for over $100M in annual net sales, with only 7,692 scripts per week needed to achieve this revenue.

Newcomers· Jan 24

The newcomer is concerned about the significant drop in price of KemPharm, Inc. ($KMPH) by 5.9%.
The newcomer thinks KemPharm, Inc. ($KMPH) has a nice chart, but is too small in terms of volume and market capitalization for their investment style.
The newcomer shares a personal experience where they lost money on KemPharm, Inc. ($KMPH) after a medicine trial succeeded, attributing it to the power of hedge funds.

Generated by AI

KemPharm

Social

May 7

Sentiment

Bullish· Jun 11

Bearish· Mar 26

Topics

Earnings· Aug 9

Announcements· Nov 29

Technical Analysis· Mar 3

Community

Regulars· Nov 18

Newcomers· Jan 24

Also Discussed

KemPharm, Inc.

Company Information

Location

Social

May 7

Sentiment

Bullish· Jun 11

Bearish· Mar 26

Topics

Earnings· Aug 9

Announcements· Nov 29

Technical Analysis· Mar 3

Community

Regulars· Nov 18

Newcomers· Jan 24

Also Discussed